PharmAust Limited announces completion of OLE study enrolment

PharmAust Limited (ASX: $PAA), a clinical-stage biotechnology company, has completed enrolment for the Open-Label Extension (OLE) study. The updated data analysis conducted by Berry Consultants shows a statistically significant survival benefit for monepantel (MPL) compared to untreated matched-controls from the Pooled Resource Open-Access ALS Clinical Trials (PRO-ACT) database for patients with Motor Neurone Disease (MND)/Amyotrophic Lateral Sclerosis (ALS). Treatment with MPL significantly reduced the risk of death by 91% when compared to PRO-ACT matched controls.

PharmAust Managing Director's Comments on OLE Study

I'm very pleased that we have completed enrolment in the OLE study as this is a significant milestone for PharmAust. The updated survival analysis conducted by Berry Consultants is extremely encouraging, as is the updated efficacy analysis that indicates MPL continued to slow the rate of disease progression in patients with MND/ALS. These results provide an exciting backdrop ahead of the anticipated commencement of the pivotal adaptive Phase 2/3 STRIKE study in H2 2024.

Summary of PharmAust's OLE Study Update

PharmAust Limited has completed enrolment for the Open-Label Extension (OLE) study, revealing impressive survival data for monepantel (MPL) compared to untreated matched-controls from the PRO-ACT database for patients with Motor Neurone Disease (MND)/Amyotrophic Lateral Sclerosis (ALS). The updated analysis conducted by Berry Consultants shows a statistically significant survival benefit, with MPL significantly reducing the risk of death by 91% when compared to PRO-ACT matched controls. The company is looking forward to the anticipated commencement of the pivotal adaptive Phase 2/3 STRIKE study in H2 2024, aiming to further advance their therapeutic developments for neurodegenerative diseases.